Inventor · disambiguated record
Jeffrey B. Stavenhagen
Also filed as: STAVENHAGEN JEFFREY · STAVENHAGEN JEFFREY B
29 granted patents·10 pending applications·1,057 citations·filing 2003–2025
97Inventor score
Files withH LUNDBECK AS16MACROGENICS INC11STAVENHAGEN JEFFREY5THERINI BIO INC3STAVENHAGEN JEFFREY B2
Top patents by PatentIndex Score
39 records- 0198US11542323B2Agents, uses and methods for the treatment of synucleinopathyH LUNDBECK AS·Filed 2020·Granted Jan 3, 2023·6 cites·24 claims
- 0298US11524995B2Agents, uses and methods for the treatment of synucleinopathyH LUNDBECK AS·Filed 2020·Granted Dec 13, 2022·6 cites·20 claims
- 0398US8003774B2Identification and engineering of antibodies with variant Fc regions and methods of using sameMACROGENICS INC·Filed 2008·Granted Aug 23, 2011·96 cites·52 claims
- 0498US7355008B2Identification and engineering of antibodies with variant Fc regions and methods of using sameMACROGENICS INC·Filed 2004·Granted Apr 8, 2008·361 cites·22 claims
- 0597US8652466B2Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibitingSTAVENHAGEN JEFFREY B·Filed 2007·Granted Feb 18, 2014·50 cites·40 claims
- 0697US8217147B2Identification and engineering of antibodies with variant Fc regions and methods of using sameSTAVENHAGEN JEFFREY·Filed 2006·Granted Jul 10, 2012·93 cites·31 claims
- 0797US8216574B2Engineering Fc antibody regions to confer effector functionSTAVENHAGEN JEFFREY·Filed 2009·Granted Jul 10, 2012·65 cites·25 claims
- 0897US7960512B2Identification and engineering of antibodies with variant Fc regions and methods of using sameMACROGENICS INC·Filed 2004·Granted Jun 14, 2011·161 cites·11 claims
- 0996US8192737B2Identification and engineering of antibodies with variant Fc regions and methods of using sameSTAVENHAGEN JEFFREY B·Filed 2008·Granted Jun 5, 2012·72 cites·12 claims
- 1095US10711069B2Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibitingMACROGENICS INC·Filed 2017·Granted Jul 14, 2020·7 cites·16 claims
- 1195US10196439B2Antibodies specific for hyperphosphorylated tau and methods of use thereofH LUNDBECK AS·Filed 2016·Granted Feb 5, 2019·23 cites·20 claims
- 1294US10934348B2Antibodies specific for hyperphosphorylated tau and methods of use thereofH LUNDBECK AS·Filed 2019·Granted Mar 2, 2021·6 cites·11 claims
- 1394US9708408B2Methods for the treatment of disease using immunoglobulins having Fc Regions with altered affinities for FcγRactivating and FcγRinhibitingMACROGENICS INC·Filed 2014·Granted Jul 18, 2017·9 cites·10 claims
- 1494US9028815B2Identification and engineering of antibodies with variant FC regions and methods of using sameSTAVENHAGEN JEFFREY·Filed 2011·Granted May 12, 2015·24 cites·10 claims
- 1593US8951517B2Identification and engineering of antibodies with variant Fc regions and methods of using sameMACROGENICS INC·Filed 2013·Granted Feb 10, 2015·19 cites·15 claims
- 1692US10479835B2Agent, uses and methods for treatmentH LUNDBECK AS·Filed 2016·Granted Nov 19, 2019·4 cites·16 claims
- 1792US10428147B2Anti-sortilin antibodies, uses and methods for treatmentH LUNDBECK AS·Filed 2016·Granted Oct 1, 2019·4 cites·7 claims
- 1890US10889650B2Agent, uses and methods for treatmentH LUNDBECK AS·Filed 2019·Granted Jan 12, 2021·2 cites·19 claims
- 1990US8697071B2Identification and engineering of antibodies with variant Fc regions and methods of using sameSTAVENHAGEN JEFFREY·Filed 2012·Granted Apr 15, 2014·15 cites·18 claims
- 2090US8445645B2Identification and engineering of antibodies with variant Fc regions and methods of using sameSTAVENHAGEN JEFFREY·Filed 2011·Granted May 21, 2013·15 cites·8 claims
- 2189US10562962B2Antibodies specific for hyperphosphorylated tau and methods of use thereofH LUNDBECK AS·Filed 2018·Granted Feb 18, 2020·6 cites·11 claims
- 2288US11548950B2Agent, uses and methods for treatmentH LUNDBECK AS·Filed 2020·Granted Jan 10, 2023·1 cites·19 claims
- 2387US11739140B2Antibodies specific for hyperphosphorylated tau and methods of use thereofH LUNDBECK AS·Filed 2021·Granted Aug 29, 2023·1 cites·12 claims
- 2486US2024018261A1METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS ALTERED AFFINITIES FOR FcyRActivating and FcyRInhibitingMACROGENICS INC·Filed 2023·Application pending·0 cites
- 2585US2023312693A1Agents, Uses and Methods for the Treatment of SynucleinopathyH LUNDBECK AS·Filed 2022·Application pending·0 cites
- 2684US12331123B2Agent, uses and methods for treatmentH LUNDBECK AS·Filed 2022·Granted Jun 17, 2025·0 cites·22 claims
- 2782US10894833B2Agents, uses and methods for treatmentH LUNDBECK AS·Filed 2018·Granted Jan 19, 2021·2 cites·4 claims
- 2882US2025277040A1Agent, uses and methods for treatmentH LUNDBECK AS·Filed 2025·Application pending·0 cites
- 2981US7388084B2Promoter motifs in Candida tropicalisCOGNIS CORP·Filed 2003·Granted Jun 17, 2008·9 cites·2 claims
- 3075US11787871B2Methods for the treatment of disease using immunoglobulins having fc regions with altered affinities for FcgammaRactivating and FegammaRinhibitingMACROGENICS INC·Filed 2020·Granted Oct 17, 2023·0 cites·20 claims
- 3166US12269894B2Antibodies which bind human fibrin or fibrinogen γC domain and methods of useTHERINI BIO INC·Filed 2024·Granted Apr 8, 2025·0 cites·21 claims
- 3263US12421303B2Agents, uses and methods for the treatment of synucleinopathyH LUNDBECK AS·Filed 2020·Granted Sep 23, 2025·0 cites·20 claims
- 3360US2021292414A1Agents, uses and methods for treatmentH LUNDBECK AS·Filed 2020·Application pending·0 cites
- 3454US2024279357A1ANTIBODIES WHICH BIND HUMAN FIBRIN OR FIBRINOGEN yC DOMAIN AND METHODS OF USETHERINI BIO INC·Filed 2022·Application pending·0 cites
- 3553US2015259396A1Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using SameMACROGENICS INC·Filed 2015·Application pending·0 cites
- 3653US2024279321A1ANTIBODIES WHICH BIND HUMAN FIBRIN OR FIBRINOGEN yC DOMAIN AND METHODS OF USETHERINI BIO INC·Filed 2022·Application pending·0 cites
- 3752US2009098124A1Identification and engineering of antibodies with variant heavy chains and methods of using sameMACROGENICS INC·Filed 2008·Application pending·0 cites
- 3849US2008112961A1Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using SameMACROGENICS INC·Filed 2007·Application pending·0 cites
- 3942US2005260213A1Fcgamma-RIIB-specific antibodies and methods of use thereofKOENIG SCOTT·Filed 2005·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →